Seeking Alpha
03 Nov 2026, 16:50 UTC · 1h ago
Impact · against what's priced in
The stock faces downward pressure due to slower-than-expected initiation of the phase 3 trial for silevertinib. While strong phase 2 data and a cash runway into H2 2028 provide a floor, the timeline delay is a negative catalyst.
No priced-in read yet
What the story claims
4 claims · scored −1 bearish … +1 bullish · 0 new · 4 priced in
The initiation of the phase 3 trial for silevertinib in 1st-line non-classical EGFRm NSCLC is occurring slower than expected.
Priced inanalysis piece by Seeking Alpha author
More negative than 87% of claims this week
Black Diamond Therapeutics has a cash position sufficient to fund operations into H2 2028.
Priced in
Continue reading
5 related stories
The slower-than-expected initiation of the phase 3 trial for silevertinib in 1st-line non-classical EGFRm NSCLC acts as a negative catalyst, offsetting the stability provided by a cash runway extending into H2 2028.
Read from the article alone
Scored by the NIS engine · methodology.
So whatThe runway through late 2028 suggests no need for dilutive equity financing for approximately 21 months.
More positive than 61% of claims this week
Silevertinib demonstrated a 60% ORR and 86% CNS ORR in phase 2 trials.
Priced inanalysis of previous phase 2 data
More positive than 47% of claims this week
Key catalysts in Q4 2026 include updated phase 2 data and FDA feedback on the pivotal phase 3 trial.
Priced inanalysis piece by Seeking Alpha author
So whatThese events within the next quarter will determine if the phase 3 timeline shifts further or stabilizes.
More positive than 47% of claims this week
Which stocks this story touches
More positive than 55% of ticker scores this week
Despite a rating downgrade due to trial delays, the analyst maintains a 'Buy' rating based on strong phase 2 data and a solid cash position.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
11h ago
+3.1%
Price is moving against the score
$1.80 vs $1.75 close before publication (Nov 2) · not market-adjusted
BDTX chart →
